Innova Biosciences has once again made a huge breakthrough in the field of biomedicine with the launch of CD34+ HSC, which is leading stem cell research. This innovative stem cell model provides scientists with more advanced and efficient tools to deeply study the biological characteristics of stem cells and their applications in the field.
Technological innovation of CD34+ HSC.
CD34+ HSC is a CD34-marked, hematopoietic stem cells model. Its outstanding technical highlights make it an important tool in the current field of stem cell research.
Key Features & Benefits:
1.Highly pure HSC population:
The CD34+ HSC model provides a highly pure hematopoietic stem cell population through precise labeling technology. This provides researchers with a more controllable environment under experimental conditions, which provides insight into the characteristics of HSCs.
2.Pluripotency and differentiation potential:
The model exhibits excellent pluripotency and differentiation potential, making it a wide range of applications in stem cells**, regenerative medicine and other fields. CD34+ HSC allows researchers to more comprehensively study the differentiation process of stem cells and their potential clinical applications.
3.Disease Modeling & Drug Screening:
CD34+ HSC can be used to mimic a wide range of hematologic-related diseases and to support drug screening and evaluation. This provides a more accurate and reliable testing platform for new drug development.
Scientific research applications and future prospects.
1.Hematopoietic Disease Research:
The CD34+ HSC model provides an ideal platform for the in-depth study of hematopoietic diseases, and is expected to reveal the pathogenesis and potential pathways of various diseases.
2.Stem Cell ** Development:
This model is expected to be a driving force for innovation in the field of stem cells, providing new directions for various diseases. The high purity and pluripotency of CD34+ HSCs provide a solid foundation for individualization**.
3.Future Innovation Direction:
Innobio is committed to advancing the research of CD34+ HSC models and further enhancing its impact in stem cell research and applications. The company will continue to invest in research and development to meet the growing research needs of scientists.
Epilogue. The launch of CD34+ HSC marks a new chapter in the field of stem cell research. The model's remarkable properties provide scientists with more advanced tools that are expected to push stem cell research to new heights.
About ModelBio: ModelBiotech (Beijing)** was founded by scientists from Novo Nordisk China R&D Center, CrownBio, and the Institute of Immunology at Shanghai Jiao Tong University. With a stable humanized mouse model platform for the immune system (HIS) and a humanized tumor xenograft platform (PDX) in China, we focus on the field of tumor and tumor immunopharmacodynamics CRO services, translational medicine research services, and personalized medicine, serving new drug R&D enterprises, translational medicine researchers, and cancer patients, and is committed to providing a new generation of clinical experimental animal models for the research and development of tumor and tumor immunity.
ModelBio**:
*：news/77.html